Navigation Links
ViaCyte Appoints Mark Foletta, former CFO of Amylin, to its Board of Directors
Date:12/19/2013

SAN DIEGO, Dec. 19, 2013 /PRNewswire/ -- ViaCyte, Inc., a leading regenerative medicine company developing a transformative cell therapy for treatment of diabetes, announced today that Mark G. Foletta has been appointed to its Board of Directors.

(Logo: http://photos.prnewswire.com/prnh/20121026/LA00871LOGO-a)

Mr. Foletta is a seasoned financial executive with over 30 years of corporate experience.  He was most recently senior vice president and Chief Financial Officer at Amylin Pharmaceuticals, Inc.  He joined Amylin in 2000 and served through its acquisition by Bristol-Myers Squibb for approximately $7 billion in August 2012.  During his time at Amylin the company grew from 75 to over 1,300 employees and he was instrumental leading numerous strategic transactions with global pharmaceutical companies, as well as public and private financing transactions.  As chair of Amylin's Operating Committee, he had responsibility for business planning, forecasting and assessing performance.  He also participated in the commercial launch of three novel pharmaceutical products that generated annual revenues reaching over $700M. 

Prior to Amylin, Mr. Foletta worked 14 years at Intermark, Inc./Triton Group Ltd. where he served as senior vice president, Chief Financial Officer and Corporate Secretary.  Mark began his career in 1982 as an Audit Manager at Ernst & Young, LLP in San Diego.  He holds a B.A. in Business Economics and is a Certified Public Accountant (currently inactive).  

"We are pleased to welcome Mark to our Board of Directors," said Paul Laikind, Ph.D., ViaCyte's president and Chief Executive Officer.  "With our promising cell replacement therapy for type 1 diabetes, the VC-01™ combination product, expected to enter the clinic next year, we will be exploring the new strategic and/or financial transactions that will continue to fuel our growth.  Mark's many years as a senior finance executive, including 12 years in the biotechnology sector with a company focused on diabetes, will undoubtedly serve us well as we navigate our way to success."

"I am looking forward to working closely with the team at ViaCyte," said Mr. Foletta.  "VC-01 holds the promise of transforming the way patients with type 1 diabetes manage their disease.  In fact, if VC-01 performs in humans as it has in animal studies, it could effectively cure the disease for patients with type 1 diabetes and be an important new therapy for those patients with insulin-dependent type 2 diabetes as well.  It is an exciting time for the company and I am pleased to lend my expertise."

Fred Middleton, ViaCyte's Chairman of the Board said, "On behalf of the board and management of ViaCyte, I want to join Paul in welcoming Mark to the team."

ViaCyte has held productive meetings with the United States Food and Drug Administration (FDA) and Health Canada and is on track to file an Investigational New Drug (IND) Application to support the initiation of clinical evaluation of the VC-01 combination product in patients with diabetes in mid-2014. 

About ViaCyte

ViaCyte is a private company focused on developing a novel cell therapy for the treatment of diabetes. The Company's technology is based on the production of pancreatic beta cell progenitors derived from human pluripotent stem cells. These cells are implanted using a durable and retrievable encapsulation device. Once implanted and matured, these cells secrete insulin and other regulatory factors in response to blood glucose levels. ViaCyte's goal is long term insulin independence without immune suppression, and without risk of hypoglycemia and other diabetes-related complications.

ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia. The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.

This news release may contain forward-looking statements made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995.

 


'/>"/>
SOURCE ViaCyte
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ViaCyte Receives $10.1 Million Strategic Partnership Award from CIRM to Continue Development of Diabetes Therapy
2. ViaCyte, Inc. raises $10.6 Million in a Private Financing to Support Clinical Development of its Cell Therapy Product for Insulin Dependent Diabetes
3. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
4. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
5. Nephros Appoints John C. Houghton as President and Chief Executive Officer
6. Elsevier Appoints New President of Elsevier CPM Resource Center
7. GenWay Biotech Appoints New Vice President of Custom/OEM
8. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
9. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
10. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
11. Hill-Rom Appoints Alton Shader President of Hill-Rom North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... York , February 5, 2016 ... Transparency Market Research report states that the global active ... 2014 and is predicted to reach US$185.9 bn by ... of 6.50% from 2014 to 2020. The title of ... Chemical/Biological, Captive/Contract Manufactured, by Geography, and by Therapeutic Area) ...
(Date:2/5/2016)... MELVILLE, N.Y. , Feb. 5, 2016  Henry ... of health care products and services to office-based dental, ... has entered into an agreement to acquire a majority ... dental supplies and equipment in Brazil ... Headquartered in Blumenau, Brazil, Dental Cremer is the dental ...
(Date:2/4/2016)... , Feb. 4, 2016 For hospitals considering ... those already participating in the program, the Health Resources ... to as the , Mega-Guidance , could have significant ... is published in September 2016. Essential Insights ... Service Marketing , summarizes the Mega-Guidance,s key proposed changes, ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... February 06, 2016 , ... ... , MEDIA ADVISORY: 5000 PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & ... nurses in the world with an estimated 5000 perioperative nurses in attendance ...
(Date:2/5/2016)... SARASOTA, Florida (PRWEB) , ... February 05, 2016 , ... ... an event he has completed every year since it started in 2003. This year, ... attracting the attention of fellow runners and NBA team the Miami Heat. , This ...
(Date:2/5/2016)... Minneapolis, MN (PRWEB) , ... February 05, 2016 , ... ... p.m. at the Day Block Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will ... , Larry Schneiderman, owner of Schneiderman’s Furniture, lives with Parkinson’s disease and is the ...
(Date:2/5/2016)... ... 05, 2016 , ... After years as an active staff surgeon and having ... surgeon Dr. Wayne Carman transitioned to chief of the Division of Plastic Surgery at ... term as chief and began a second three-year term in January of 2016. , ...
(Date:2/5/2016)... ... , ... Regular gym users know the routine: each January, they see a ... treadmills. It’s a predictable trend. After the excesses of November and December, people make ... joining gyms, starting new walking or running routines, or signing up for Zumba. And ...
Breaking Medicine News(10 mins):